AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01223183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hypertonic saline (7%)
Description: single treatment by inhalation
Study NCT01223183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isotonic saline
Description: single treatment by inhalation
Study NCT02145065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local drug delivery via microcrystalline paclitaxel balloon coating (PAK,Balton, Poland)
Study NCT02145065 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plain balloon angioplasty, uncoated balloon (Neptun, Balton, Poland)
Study NCT03133351 — intervention group
Intervention type: DEVICE
Intervention: PCM
Description: A fresh whole blood sample will be tested by PCM to determine the reference range.
Study NCT00557453 — intervention group
Intervention type: DRUG
Intervention: Antibiotic treatment
Description: Cefuroxime 750mg X3/d, Ampicillin 2G X4/d, Flagyl 500mg X3/d, Augmentin 1G X3/d, Gentamycin 240mg X1/d, Clindamycin 600mg X3/d, Ciprofloxacin 400mg X2/d All drugs will be administered IV until clinical improvement.
Study NCT00557453 — intervention group
Intervention type: DRUG
Intervention: No antibiotics
Description: Allowed medications for both groups will include PPI / H2 blockers, home medication, SC insulin for diabetes, and SC clexane if indicated.
Study NCT02260947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06273340
Description: PF-06273340 50 mg
Study NCT02260947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06273340
Description: PF-06273340 400 mg
Study NCT02260947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin 300 mg
Study NCT02260947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 600 mg
Study NCT02260947 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study NCT03759691 — intervention group
Intervention type: BEHAVIORAL
Intervention: Structured interview
Description: Interview contains questions about stroke knowledge and help-seeking behaviour on the day the stroke occured.
Study NCT00543335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Starting dose 200 mg PO (by mouth) Daily
Study NCT00543335 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 45 Gy total in 15 radiation treatments: 3 Gy per day, 5 days a week for 3 weeks
Study NCT00811174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octagam 10%
Description: 300-600 mg/kg every 21 (+/- 3 days) to 28 days (+/- 3 days)
Study NCT01634087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered orally
Study NCT01848132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Vincristine: intravenous, 1,4 mg/m2, day 1
Study NCT02179216 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydration
Description: Hydratation the first day in the arm 1 Hydration the second day in the arm 2
Study NCT02179216 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Venous contention
Description: Venous contention the second day in the arm 1 Venous contention the first day in the arm 2
Study NCT03709394 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full utrasound guidance
Description: The target vein is directly identified by portable ultrasound device and the complete procedure of peripheral venous cathether insertion is controlled by ultrasound guidance in real time
Study NCT03709394 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial ultrasound guidance
Description: The target vein is directly identified by ultrasound but the procedure of peripheral venous cathether insertion is performed conventionally, without ultrasound guidance
Study NCT00433563 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Twice daily radiotherapy
Description: Standard of care chemotherapy (cisplatin/etoposide) + twice daily radiotherapy
Study NCT00433563 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Twice daily radiotherapy
Description: Standard of care chemotherapy (cisplatin/etoposide) + twice daily radiotherapy
Study NCT04640519 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care patients will be seen by a primary care nurse practitioner and a stroke neurologist.
Study NCT04640519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TASC intervention
Description: TASC patients will receive a BP monitoring kit and electronic tablet with patient tailored BP infographics. They will be scheduled with 5 telehealth visits over 3 months, including primary care nurse practitioner, pharmacy and stroke neurologist.
Study NCT03141281 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BrainHQ
Description: BrainHQ
Study NCT03141281 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rise of Nations
Description: Rise of Nations
Study NCT01853904 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bronchoscopy/ BAL with Channel Suction
Description: The wall suction used for the channel suction will be set at 80 mm Hg. This arm is for patients who will receive channel suction first to obtain the specimen then syringe suction to obtain the specimen.
Study NCT03141281 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IADL Training
Description: IADL Training
Study NCT03141281 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Puzzle solving
Study NCT03193411 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Visumax femtosecond laser
Study NCT03193411 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Moria M2 microkeratome (MK)
Study NCT01853904 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bronchoscopy/BAL with Syringe Suction
Description: Syringe based suctioning will be performed with 20mL syringe.
Study NCT02910167 — intervention group
Intervention type: DRUG
Intervention: Hyoscine n-butylbromide
Description: Hyoscine n-butylbromide 10 mg
Study NCT02910167 — intervention group
Intervention type: DRUG
Intervention: Paracetamol
Description: Paracetamol 500 mg
Study NCT04636333 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14
Description: Two doses of middle-dose (20µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14.
Study NCT04636333 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28
Description: Three doses of middle-dose (20µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28.
Study NCT04904133 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low/No Calorie Sweeteners
Description: LNCS powdered and then dissolved in water.
Study NCT03155035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Albendazole 400 mg chewable tablets (200 mg each) Two tablets as a single dose recommended as ovicidal, larvicidal and vermicidal against all soil transmitted helminths
Study NCT03155035 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium 400 mg + Vitamin D 2.5 mcg
Description: 2 chewable tablets provide recommended daily allowance for calcium and vitamin D
Study NCT04904133 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: Water
Study NCT03709394 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No ultrasound guidance
Description: The target vein is identified and peripheral venous catheter is inserted by conventional approach without use of any guiding devices
Study NCT03244163 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spyglass DS cholangioscope
Description: The 1.8Fr holmium:YAG laser fiber (Lumenis, Yokneam, Israel) will be inserted into the cholangioscope's working channel for lithotripsy under direct visualization. An EHL probe may alternatively be used depending on availability. Lithotripsy is applied until fragments of the targeted stone are no longer lumen filling, and can be dispersed easily with fluid irrigation. Fragmented stones are then removed by a combination of conventional techniques. To confirm stone clearance, the Spyglass DS cholangioscope will be re-introduced, and the bile duct will be examined for residual stones from the confluence of the right and left intrahepatic ducts to the papillary opening
Study NCT03244163 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BML
Description: Biliary sphincterotomy with/without EPBD to the size of the lower bile duct with a limit of 15mm will be performed. Stones are removed by a combination of conventional BML, extraction balloon and/or baskets, without laser lithotripsy. An occlusion cholangiogram is performed to confirm stone clearance. In cases where stone clearance is incomplete, a plastic biliary stent bridging the stone will be inserted for temporary drainage until definitive management, usually within one month.
Study NCT04045678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03003 ( Rotigotine, extended-release microspheres)
Description: Patients to be enrolled to 70 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week and then 70 mg in the next 5 weeks.~Patients to be enrolled to 84 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week, 70mg in the fifth week and then 84 mg in the next 5 weeks.
Study NCT04045678 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, extended-release microspheres
Description: Patients to be enrolled to 70 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week and then 70 mg in the next 5 weeks.~Patients to be enrolled to 84 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week, 70mg in the fifth week and then 84 mg in the next 5 weeks.
Study NCT03030079 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Electrical Stimulation Regimen
Description: The electrodes will pass an electrical current through the skin and into the muscle first at a low intensity for 5 minutes to allow the subject to adjust to the sensation. The current will then be gradually increased to a level sufficient to elicit a non-painful motor contraction. The subject will sit in a relaxed position as the electrical stimulator contracts the muscles for a duration of 15 minutes.
Study NCT02665208 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual (TAU)
Description: informational pamphlets and information from 1800 quit line + prescription for nicotine replacement therapy (NRT) based on on the quantity of baseline self-reported smoking, or nicotine replacement gum (2mg)
Study NCT02665208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapies
Description: a prescription for a nicotine replacement therapy (NRT) (i.e. nicotine replacement patches based on the quantity of baseline self-reported smoking, or nicotine replacement gum (2mg)
Study NCT02665208 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text Message Intervention (TMI)
Study NCT02028988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Study NCT02028988 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation
Study NCT01452464 — intervention group
Intervention type: BIOLOGICAL
Intervention: MenACWY-CRM
Description: MenACYW-CRM vaccination received as part of routine clinical care and as registered in the vaccine records.
Study NCT04636333 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14
Description: Two doses of high-dose (40µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHOCell) at the schedule of day 0, 14.
Study NCT04636333 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28
Description: Three doses of middle-dose (40µg/0.5ml) recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28.
Study NCT02680639 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiPAP Synchrony ventilator
Description: The BiPAP Synchrony ventilator will be used to determine Expiratory Positive Airway Pressure (EPAP). The ventilator will be used with varying pressure supports and oscillations depending on what arm of the study the participant is in.
Study NCT02680639 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BiPAP Synchrony ventilator
Description: The BiPAP Synchrony ventilator will be used to determine Expiratory Positive Airway Pressure (EPAP). The ventilator will be used with varying pressure supports and oscillations depending on what arm of the study the participant is in.
Study NCT00747435 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric Acoustic System
Description: Combination of a cochlear implant and a hearing aid
Study NCT03027895 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumen-apposing metal stent (LAMS)
Description: Endoscopic Ultrasound-guided Drainage of WON with LAMS
Study NCT03027895 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Double pigtail plastic stent (DPPS)
Description: Endoscopic Ultrasound-guided Drainage of WON with DPPS
Study NCT02813603 — intervention group
Intervention type: PROCEDURE
Intervention: EBUS
Description: 19G and 22G EBUS needles are compared in a randomized prospective way in lung cancer patients with enlarged mediastinal lymph nodes.
Study NCT02113956 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guy2Guy (G2G)
Description: G2G is a text messaging-based healthy sexuality and HIV prevention program specifically for 14-18 year old GBQ adolescent males. Content is guided by the Information-Motivation-Behavioral Skills (IMB) model and focuses on: HIV information, motivations to engage in HIV preventive behavior, communication skills, behavioral skills (e.g., using a condom; HIV testing); and healthy/unhealthy relationships. Behavioral skills content is reinforced using brief online videos. The intervention is 5 weeks long. A booster is delivered 6-weeks post-intervention end and reviews the topics covered in the intervention. G2G content is tailored based upon whether one is abstinent or sexually active.
Study NCT00604461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin, Bevacizumab and Pemetrexed
Description: Chemotherapy was given for 2 cycles after maximal response. Patients were taken off study at the time of progression. If the patient had stable disease or better, as a response, then the patient was maintained on pemetrexed plus bevacizumab for a total of one year after initiation of maintenance or until progression which ever occured first. Computed tomography (CT) scans were be done every 12 weeks during the maintenance phase.
Study NCT04636333 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Two doses of placebo at the schedule of day 0, 14 #middle-dose group#
Description: Two doses of placebo (0.5ml) at the schedule of day 0, 14.
Study NCT03662009 — intervention group
Intervention type: OTHER
Intervention: multilimb dual task
Description: control of arm and foot in two attentional contexts of simulated driving
Study NCT04429672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Right to your Sexual Health
Description: which is of a socio-educational type and is made up of five thematic axes; Sexual Rights, Sexuality, Reproductive Health, Sexual Behavior and Life Project divided into ten sessions (two weekly) of 30 minutes each, each session has a structure of opening, development and closing phase
Study NCT04429672 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Friendly sexual health services and reproductive for adolescents
Description: consists of six sessions (one a week) lasting 50 minutes each, using illustrative material through official flipcharts of the secretary of health on reproductive health, sexually transmitted diseases and sexual violence
Study NCT03242863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food proportionality
Description: Proportions of high and low energy dense foods manipulated
Study NCT04636333 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Three doses of placebo at the schedule of day 0, 14, 28 #middle-dose group#
Description: Three doses of placebo (0.5ml) at the schedule of day 0, 14, 28.
Study NCT04636333 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Two doses of placebo at the schedule of day 0, 14 #High-dose group#
Description: Two doses of placebo (0.5ml) at the schedule of day 0, 14.
Study NCT04192461 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth guided immediate implant placement
Description: The technique of implant insertion consisted of a progressive preparation of the implant site using the anatomy of the root of the multi-radicular mandibular molars to be extracted as a reference and as an aid to engage the inter-radicular septum
Study NCT00372840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Study NCT00837343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine fumarate tablet (Seroquel)
Description: Investigational product: quetiapine fumarate tablet (Seroquel) , 25 mg, 200 mg, 300mg, manufactured by AstraZeneca.The total daily doses of quetiapine fumarate will be increased to 600mg/d on the 6th since enrolment day. At day 7 or later, the dose can be adjusted in the range of 400- 800mg/day.
Study NCT03725813 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Person-centred inpatient care
Description: The intervention comprises three sequential steps in the care process. The first two steps follow one after the other in conjunction with admission to the ward: 1) person-centred assessment, and 2) creation of a person-centred health plan. Persistent person-centred inpatient care, the third step, is practiced throughout the hospital stay, and is a component of the quality and patient safety program.~The model is systematically applied to all patients admitted to the unit. All staff are trained in PCC before implementation of the intervention.
Study NCT02412046 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Muscle biopsy
Study NCT00372840 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: psychosocial assessment and care
Study NCT00372840 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Study NCT02854527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: single dose
Study NCT02854527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: single dose
Study NCT02854527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: single dose
Study NCT02854527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: single dose
Study NCT02854527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: 0.25 mg digoxin as single dose (all 4 drugs given together as a cocktail at the same time point)
Study NCT02854527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: 1 mg furosemide as single dose (all 4 drugs given together as a cocktail at the same time point)
Study NCT02854527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin hydrochloride
Description: 10 mg metformin hydrochloride as single dose (all 4 drugs given together as a cocktail at the same time point)
Study NCT02854527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 10 mg rosuvastatin as single dose (all 4 drugs given together as a cocktail at the same time point)
Study NCT00098618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally
Study NCT00098618 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa
Description: Given orally
Study NCT00098618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03744624 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic liver resection
Description: Laparoscopic liver resection for oncological purposes
Study NCT03744624 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic liver resection
Description: Laparoscopic liver resection for oncological purposes
Study NCT03744624 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D printing model
Description: Use of 3D printed liver model in decision-making: preoperative planning and intraoperative guidance.
Study NCT00643812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Installation of gun locker in household
Description: Households were randomized to 'early' and 'late' arms. Each household received a gun locker, which was installed in the household. Early arm received gun lockers at baseline.
Study NCT00643812 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Installation of gun locker in household
Description: Households were randomized to 'early' and 'late' arms. Each household received a gun locker, which was installed in the household. Late arm received the gun locker 12 months after baseline.